Skip to main content
XORTX Therapeutics Inc. logo

XORTX Therapeutics Inc. — Investor Relations & Filings

Ticker · XRTX ISIN · CA98420Q2071 LEI · 254900RAT3XZPF9F9350 US Manufacturing
Open in API
Filings indexed 263 across all filing types
Latest filing 2024-10-18 Regulatory Filings
Country CA Canada
Listing US XRTX

About XORTX Therapeutics Inc.

https://www.xortx.com/

XORTX Therapeutics Inc. is a late-stage clinical biopharmaceutical company that develops and commercializes therapies for diseases associated with aberrant purine metabolism and high serum uric acid. The company's pipeline focuses on progressive kidney diseases, including Autosomal Dominant Polycystic Kidney Disease (ADPKD), Type 2 Diabetic Nephropathy (T2DN), and Acute Kidney Injury (AKI), as well as gout. Its lead program, XRx-008, is in development for the treatment of ADPKD.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release as Exhibit 99.1 dated October 18, 2024. The document length is short (1232 characters) and primarily serves as a regulatory filing to report the issuance of a press release. There is no substantive financial data or detailed report content present. According to the rules, such filings are classified as Regulatory Filings (RNS) because they do not contain the full report or detailed financial statements but rather announce or attach other documents.
2024-10-18 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XORTX Therapeutics Inc., pursuant to SEC rules. It includes legal opinions as exhibits regarding the legality of securities being registered. The document is short (1866 characters) and primarily serves as a regulatory filing to report information to the SEC, without containing financial statements or detailed financial analysis. It does not represent an annual report, earnings release, or other substantive financial report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 6-K that do not fit other categories.
2024-10-18 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details an offering of common shares and pre-funded warrants by XORTX Therapeutics Inc., including pricing, terms, and conditions of the securities being offered. The document includes information about the securities purchase agreement, placement agent fees, listing applications, and risk factors. It is a detailed disclosure document related to a capital raising transaction rather than a financial report, earnings release, or management discussion. Therefore, it fits the category of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2024-10-18 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1231 characters), and it primarily serves as a regulatory announcement of a press release rather than a full financial report. According to the rules, such filings are classified as Regulatory Filings (RNS) because they do not contain the full report but rather an announcement or supplementary information.
2024-10-17 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an 'at the market' offering of common shares. It discusses suspension and termination of a continuous offering under a Sales Agreement and references registration and sales of shares. This type of document is an update on capital raising activities and financing arrangements, not a full financial report or earnings release. It is not an announcement of voting results, management changes, or legal proceedings. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and focused on financing details, confirming this classification.
2024-10-17 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed pursuant to SEC rules under the Securities Exchange Act of 1934. It includes a signature by the CEO and references an attached press release (Exhibit 99.1). The document length is short (1227 characters), and it primarily serves as a regulatory filing to report current information, including the press release. There is no substantive financial data or detailed report content such as an annual or quarterly report. According to the rules, Form 6-K filings are best classified under Regulatory Filings (RNS) as they are miscellaneous regulatory announcements that do not fit other specific categories.
2024-10-09 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.